Controlled Release
Precision Delivery
Advanced Controlled Release Excipient System
COAT ICON® CR is an innovative range of extended-release (ER) excipient systems designed for the formulation of slow or controlled-release oral solid dosage forms. The system comprises a synergistic blend of substantially uncross-linked carboxymethyl starch or sodium starch glycolate (SSG), combined with hydrophilic, non-ionic cellulose ethers — preferably hydroxypropyl methylcellulose (HPMC) to form a controlled-release matrix.
The COAT ICON® CR range is engineered to ensure consistent drug release over an extended period, enhancing therapeutic outcomes and improving patient compliance.
Versatile Applications
Ensuring Steady Dissolution and Diffusion of APIs
- Uses multiple grades of Hypromellose (HPMC)
- Forms a gel barrier upon hydration
- Slows penetration of gastrointestinal fluids
- Enables sustained and predictable drug release
Key Advantages
Controlled and Sustained Drug Release
The HPMC-based matrix system effectively modulates the drug release rate, providing prolonged therapeutic activity with reduced dosing frequency.
Proven Pharmaceutical Excipient
HPMC, used in combination with other approved excipients in the COAT ICON® CR system, is a well-established excipient with an extensive history of safe and effective use in ER tablet formulations across a broad spectrum of therapeutic agents.
Broad Compatibility
COAT ICON® CR systems are suitable for use with a wide range of active pharmaceutical ingredients (APIs) and can be adapted to various ER tablet design requirements.
Example Formulations Available
COAT ICON® CR formulations are readily available for several ER tablets, including but not limited to:
- Metformin Hydrochloride ER tablets (various strengths)
- Diclofenac Sodium ER tablets
- Metoprolol Succinate ER tablets
- Paracetamol ER tablets
- Acetaminophen ER tablets
- Gliclazide ER tablets
- Aceclofenac ER tablets
Regulatory Information:
COAT ICON® CR systems, featuring HPMC in combination with other approved excipients, comply with regulatory standards for excipient use in ER formulations. The desired ingredients are widely recognized by global health authorities, including the US FDA and EMA, for its role in forming hydrophilic matrices in controlled-release systems. It has a longstanding record of safety, efficacy, and regulatory acceptance in pharmaceutical applications.